Scope and Patent Landscape for US Patent No. 12,616,806 (Fluticasone Propionate + Carbon Dioxide Acidification via Patient-Exhalation Nasal Delivery)
The US patent 12,616,806 claims methods for treating chronic rhinosinusitis (with nasal polyps or without) using a patient-worn delivery housing that uses exhalation-driven bidirectional airflow to aerosolize fluticasone propionate and contemporaneously deliver carbon dioxide to an upper posterior nasal region to reduce local pH by a narrow target margin, using specific CO2 concentration, flow rate, and delivery duration. The enforceable claim core centers on the combination of: (i) liquid aerosol administration of fluticasone propionate during exhalation, (ii) timing where CO2 is delivered before or at the same time as fluticasone, (iii) delivery of CO2 to an “upper posterior” site, and (iv) a defined magnitude of pH reduction achieved via CO2 delivery parameters.
What is the exact claim scope of US 12,616,806 for treating chronic rhinosinusitis with nasal polyps and without?
Independent claim 1: What must be present for infringement
Claim 1 is a composite method claim. To infringe, an accused activity must practice all steps in one “method of treating” sequence, including device-handling and physiochemical dosing parameters.
A. Indication and patient
- Treat chronic rhinosinusitis with nasal polyps.
B. Device placement and exhalation-driven airflow
- Place a nosepiece into a first nostril.
- Place a mouthpiece into the mouth.
- Mouthpiece is fluidly connected to the nosepiece by a flow path such that exhalation by the patient into the mouthpiece and out of the nosepiece produces bi-directional fluid flow of exhalation air into a first nasal passageway and out of a second nasal passageway.
This ties infringement to patient exhalation physiology and the specific mouth-to-nose fluidic coupling.
C. Thumb/finger actuation to meter fluticasone propionate
- Manually depress a chamber using thumb or finger to:
- activate a pump and
- flow fluticasone propionate from the chamber to the nosepiece.
- Open a valve in the flow path from mouthpiece to nosepiece in response to manually depressing the chamber.
This creates an actuation-linked release mechanism: pump and valve actuation are causally coupled.
D. Fluticasone administration as a liquid aerosol during exhalation
- Administer fluticasone propionate as a liquid aerosol during exhalation through the nosepiece.
- The delivery requires that aerosol formation/administration occurs contemporaneously with the patient’s exhale event.
E. Carbon dioxide delivery location
- Deliver carbon dioxide during exhalation to a location at an upper posterior region of the first nasal passageway.
This is a spatial limitation. It is not “anywhere in the nasal cavity”; it is a defined anatomical target region.
F. Carbon dioxide-induced pH reduction with tight bounds
- Reduce a pH at the location at the upper posterior region of the first nasal passageway by 0.1 to 0.2 pH units by:
- controlling fluid flow to deliver CO2 at:
- 5% vol/vol to 6% vol/vol CO2, and
- fluid flow rate ≥ 20 L/min
- for duration 2 to 3 seconds.
- Timing relationship: CO2 is delivered before or at the same time as fluticasone propionate.
This is the chemical/physical “signature.” It is enforceable even if the fluticasone amount varies, as long as the CO2 achieves the claimed pH reduction under the specified CO2 concentration, flow rate, and time window, with the claimed timing.
Dependent claims 2-21: What changes within the same infringement perimeter
These dependents narrow or add specific elements while remaining inside the same core concept.
Fluticasone dosage dependents (claims 2-4, 16-18, 19-21)
- 400 μg b.i.d. (several dependents)
- 200 μg b.i.d. (several dependents)
- 100 to 400 μg b.i.d. (several dependents)
Valve/exhalation flow character (claim 5 and 47)
- Fluid flow is delivered as a burst of air on opening of the valve.
Mechanical alignment (claim 6 and 43’s integrated alignment)
- Chamber, pump and nosepiece are axially aligned.
Nozzle proximate the nosepiece (claims 7, 15, 28, 36, 48, 55)
- Fluticasone is flowed through a nozzle proximate the nosepiece during exhalation.
Simultaneous delivery framing (claims 8, 15, 29, 36)
- Administering fluticasone further comprises simultaneously delivering fluticasone and exhalation air to the first nasal passageway.
Chamber motion inside housing (claim 9 and 14/43’s integrated language)
- Manual depressing comprises axially moving the chamber within an aperture in the housing.
Flow path geometry (claims 10-13, 31-34, 33-34, 49)
- Exhalation air flows through a delivery channel extending from valve toward nosepiece.
- Delivery channel inwardly tapers as it extends toward the nosepiece.
Independent claim 22: What changes for “without nasal polyps”
Claim 22 mirrors claim 1 with the same delivery mechanics and CO2/pH specifications, but changes indication:
- Treat chronic rhinosinusitis without nasal polyps.
Independent claim 43: Integrated device geometry + simultaneity constraints
Claim 43 adds integrated structural limitations (not just dependents) into the independent body:
- chamber/pump/nosepiece axially aligned
- flow path includes a delivery channel inwardly tapering from valve toward nosepiece
- fluticasone and exhalation air simultaneously delivered
This claim is narrower than claim 1, but it is still enforceable independently if all integrated geometry and timing conditions are met.
Independent claim 50: “Without nasal polyps” integrated geometry
Claim 50 mirrors claim 43 but for “without nasal polyps,” retaining axially aligned components and inwardly tapering delivery channel and simultaneous delivery.
Which claim elements are likely the infringement “linchpins” for US 12,616,806?
The strongest, most differentiating elements are the physiochemical and timing constraints rather than the generic idea of “delivering fluticasone intranasally.”
Top linchpins (high value in validity and infringement)
- Upper posterior nasal delivery site for CO2.
- CO2 concentration window: 5% to 6% vol/vol.
- CO2 delivery parameters: ≥ 20 L/min for 2 to 3 seconds.
- pH reduction magnitude: 0.1 to 0.2 pH units.
- Timing relationship: CO2 delivered before or at the same time as fluticasone.
- Exhalation-driven bidirectional flow using a mouthpiece/nosepiece housing.
- Liquid aerosol fluticasone administration during exhalation.
Likely non-linchpins (can be designed around easier)
- Specific fluticasone dosing (200 vs 400 μg b.i.d.) because multiple ranges are covered (100-400 μg b.i.d. and specific values).
- Nozzle presence, channel tapering, axial alignment, and burst behavior because these appear in dependents or are integrated only in certain independent claims (43/50). Claim 1 and 22 can still be asserted without those specific geometry dependents, so these features are not required for every infringement scenario but can matter for narrower claim strategies.
How many claims and claim types does US 12,616,806 contain, and what is the breadth split?
Based on the provided claim set (1-56), the landscape is mostly method-of-treatment with multiple dependent variations and four independent claims.
Independent method claims:
- Claim 1: chronic rhinosinusitis with nasal polyps
- Claim 22: chronic rhinosinusitis without nasal polyps
- Claim 43: with nasal polyps + integrated alignment/taper/simultaneity constraints
- Claim 50: without nasal polyps + integrated alignment/taper/simultaneity constraints
Dependent claims:
- Dose variants, flow burst form, axial alignment, nozzle proximity, simultaneous delivery, chamber motion, delivery channel taper.
Breadth split (practical)
- Widest scope: Claim 1/22 because they include core exhalation-air bidirectional flow, liquid aerosol fluticasone during exhalation, CO2 delivery to upper posterior nasal region, and the CO2/pH/time/concentration/timing envelope. They are less encumbered by additional structural geometry requirements.
- Narrowest scope: Claim 43/50 due to integrated geometric and simultaneity constraints.
What patents or prior art are most likely implicated by the fluticasone + exhalation aerosol + CO2/pH mechanism?
No actual patent list, cited references, or prosecution history was provided for US 12,616,806. Without the patent document itself (specifically the “References Cited” section and claim construction record), an accurate, source-backed prior-art landscape cannot be produced.
Per the record constraints, this analysis focuses strictly on the claims supplied: the likely implicated prior-art classes are identifiable conceptually but cannot be mapped to specific US publications, EP families, or listed citations without the patent’s bibliographic and citation data.
What does the claim language imply about device architecture (and where are design-around opportunities)?
Device architecture implied by claim steps
- A housing with:
- a nosepiece inserted into one nostril
- a mouthpiece inserted into the mouth
- A flow path linking mouthpiece to nosepiece to create bidirectional exhalation airflow.
- A chamber actuated by thumb/finger that drives a pump supplying liquid fluticasone propionate to the nosepiece.
- A valve that opens in response to chamber depression, controlling the airflow path from mouth to nose during exhalation.
- A delivery route delivering:
- CO2 to an upper posterior nasal region at a defined concentration and flow/time
- fluticasone as a liquid aerosol in the same exhalation event, with CO2 before or simultaneous.
Design-around levers (claim-scope rejections)
The tightest claim filters are measurable in practice:
- change CO2 concentration away from 5-6% vol/vol
- change the duration away from 2-3 seconds
- change flow rate below 20 L/min
- change pH reduction outside 0.1-0.2 pH units at the upper posterior region
- shift CO2 timing to after fluticasone delivery
- deliver CO2 to a different nasal region (not “upper posterior region” of the first nasal passageway)
- remove the mouthpiece-to-nose bidirectional exhalation flow mechanism
- stop administering fluticasone as a liquid aerosol during exhalation
These levers are the most direct ways to step outside claim 1/22.
How does US 12,616,806 compare with mainstream intranasal fluticasone therapies in terms of patentability differentiators?
Standard fluticasone intranasal approaches typically focus on:
- drug formulation (suspensions, solutions)
- actuator geometry
- dosing regimen
The claim set here differentiates via:
- exhalation-linked bidirectional airflow using a mouthpiece/nosepiece housing
- liquid aerosol delivery specifically “during exhalation”
- co-delivery of CO2 at narrowly defined concentration and flow/time, with a required measured pH reduction at an upper posterior nasal location.
The enforceability is therefore likely to hinge on whether an accused product:
- produces the same physiochemical effect (pH reduction range) and
- uses the same timing relative to fluticasone
- uses the specific exhalation-driven bidirectional flow device mechanics.
What is the Orange Book or FDA regulatory status of US 12,616,806?
No FDA product identification, NDA/BLA reference, Orange Book listing, or regulatory pathway information is provided with the patent number and claims excerpt. Without that mapping, the Orange Book and exclusivity status cannot be determined.
Key Takeaways
- US 12,616,806 is centered on a combination method: fluticasone propionate delivered as a liquid aerosol during patient exhalation, paired with contemporaneous or pre-fluticasone CO2 delivery to an upper posterior nasal region that induces a 0.1 to 0.2 pH reduction, using 5%-6% CO2, ≥20 L/min, and 2-3 seconds.
- Claims 1 and 22 are broad within the core concept (with vs without nasal polyps) and are the primary enforcement anchors.
- Claims 43 and 50 are narrower by embedding mechanical/channel geometry constraints (axial alignment and inward taper) and simultaneity framing into the independent claim body.
- The most defensible “claim lock” elements are the CO2/pH/flow/time/timing constraints and the upper posterior nasal target.
FAQs
-
Does US 12,616,806 require delivering carbon dioxide to both nasal passages?
Claim language requires CO2 delivery to a location at an upper posterior region of the first nasal passageway; it does not state bilateral CO2 delivery as a required element.
-
Can the fluticasone dose vary and still meet the claim?
Yes. The claim set includes dose dependents covering 100-400 μg b.i.d. and specific 200 or 400 μg b.i.d. values, while the independent claim 1/22 itself is not limited to one dose amount in the provided excerpt.
-
Is CO2 delivery allowed before fluticasone or must it be simultaneous?
The independent claim permits CO2 delivery before or at the same time as fluticasone.
-
What is the practical fastest route to a claim-scope design-around?
Adjust one of the measurable CO2 parameters (concentration, flow rate, duration), shift the timing relative to fluticasone, or change the delivery site away from the claimed upper posterior region.
-
Do the device geometry constraints (axial alignment, inward taper) apply to every claim?
No. They are integrated into independent claims 43/50 and also appear as dependent limitations; independent claims 1 and 22, as provided, do not require those specific geometry constraints.
References
- US Patent No. 12,616,806 (claims excerpt provided in prompt).
